小剂量替罗非班与双抗治疗进展性脑卒中的疗效对比及安全性评价

目的对比替罗非班和双抗治疗进展性脑卒中的疗效,并评价其临床安全性。方法选取2015-07—2016-10我院神经内科确诊的60例急性进展性脑梗死患者,且1周内病情进展,神经功能缺损较前加重。其中28例采用小剂量替罗非班治疗后接受双抗治疗为实验组,32例仅接受双抗治疗为对照组。治疗3d、7d后,比较2组NIHSS评分、BI指数、血小板计数、各项出凝血指标及出血等并发症。结果治疗3d后2组NIHSS评分差异有统计学意义(P0.05),BI指数差异无统计学意义(P0.05);治疗7d后2组间NIHSS评分及BI指数差异有统计学意义(P0.05)。结论替罗非班治疗进展性脑卒中的疗效显著,安全性良好,可提高患者预后质量。

Comparison between small dose of tirofiban and aspirin combined with clopidogrel in the treatment of progressive stroke in terms of efficacy and safety

Objective To compare the clinical efficacy between tirofiban and aspirin combined with clopidogrel in treatment of progressive stroke and to evaluate their safety.Methods We selected 60 patients with acute stroke from July 2015 to October 2016,whose condition developed into progressive stroke within one week and neurological deficit scores were aggravated.28 cases who initially received small dose of tirofiban and later received aspirin combined with clopidogrel were selected as study group,while other 32 cases merely treated with aspirin plus clopidogrel were selected as control group.Three and seven days after treatment,NIHSS scores,BI index,platelet count,coagulation indicators,bleeding and other complications were compared between two groups.Results Three days after treatment,the NIHSS scores of two groups showed significant difference(P<0.05),while BI index showed no difference(P>0.05).Seven days after treatment,both NIHSS scores and BI index between two groups were significantly different(P<0.05).Conclusion Small dose of triofiban has a promising effect on treating progressive stroke with good security,which can improve patients' prognosis.